Current Issues of Pharmacy and Medical Sciences

Developing a diagnostic test to identify the selected mutation within the CFTR gene that determines the onset of cystic fibrosis

Curr Issues Pharm Med Sci., Vol. 31, No. 4, 200-203

Angelika Szymczak1, Piotr Ksiazek1, Sylwia Mojsym-Korybska1
Wojciech Skorupa2, Albertyna Zbikowska-Machul3

Department of Public Health Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
Clinic of Tuberculosis and Lung Diseases in Warsaw, Plocka 26, 01-138 Warszawa, Poland
Independent Public Health Care Center in Puławy, Bema 1, 24-100 Pulawy, Poland

DOI: 10.1515/cipms-2018-0037


Cystic fibrosis is one of the most common genetic diseases among Caucasians due to its prevalence. Modern methods of molecular diagnostics and treatment of the disease allow to prolong the life of patients. In order to apply the appropriate treatment, the genetic basis of this disease should, however, first be known. The most common and the most severe mutation present in the CFTR gene (60-70% of cases) takes the form of an allele. This is responsible for the deletion of phenylalanine in position 508 (Δ508) of the CFTR protein. Determination of mutations in the CFTR gene using molecular techniques makes it possible to identify the causes of the disease in people who do not show the characteristic symptoms of cystic fibrosis.


CF – cystic fibrosis, CFTR – cystic fibrosis transmembrane conductance regulator, EnaC – epithlial sodium channel, ROMK – renal outermedullary potassium channel, ORCC – outwardly rectifying chloride channel, CBAVD – congenital bilateral absence of the vas deferent, WHO – World Health Organization, ECFTN – European Cystic Fibrosis Society, PCR – polymerase chain reaction. 


September 2020

Mon Tue Wed Thu Fri Sat Sun
  01 02 03 04 05 06
07 08 09 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30